Matinas Biopharma

4:30 PM - 4:45 PM (PDT), Monday, June 13, 2022
Matinas BioPharma is a biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology. Matinas' lead asset is MAT2203, an oral LNC formulated amphotericin B currently in Phase 2 with a planned pivotal to start in 2022.
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
New Jersey
Company HQ Country:
United States
Year Founded:
Not Provided
Main Therapeutic Focus:
Lead Product in Development:
MAT2203 oral amphotericin B
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2- MAT2203 and LNC platform